Children's Cancer Institute, Randwick, NSW, 2031, Australia.
Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, London, UK.
J Neurooncol. 2019 Jan;141(2):253-263. doi: 10.1007/s11060-018-03038-2. Epub 2018 Nov 16.
Diffuse intrinsic pontine glioma is the most aggressive form of high grade glioma in children with no effective therapies. There have been no improvements in survival in part due poor understanding of underlying biology, and lack of representative in vitro and in vivo models. Recently, it has been found feasible to use both biopsy and autopsy tumors to generate cultures and xenograft models.
To further model development, we evaluated the collective international experience from 8 collaborating centers to develop DIPG pre-clinical models from patient-derived autopsies and biopsies. Univariate and multivariate analysis was performed to determine key factors associated with the success of in vitro and in vivo PDX development.
In vitro cultures were successfully established from 57% of samples (84.2% of biopsies and 38.2% of autopsies). Samples transferred in DMEM media were more likely to establish successful culture than those transported in Hibernate A. In vitro cultures were more successful from biopsies (84.2%) compared with autopsies (38.2%) and as monolayer on laminin-coated plates than as neurospheres. Primary cultures successfully established from autopsy samples were more likely to engraft in animal models than cultures established from biopsies (86.7% vs. 47.4%). Collectively, tumor engraftment was more successful when DIPG samples were directly implanted in mice (68%), rather than after culturing (40.7%).
This multi-center study provides valuable information on the success rate of establishing patient-derived pre-clinical models of DIPG. The results can lead to further optimization of DIPG model development and ultimately assist in the investigation of new therapies for this aggressive pediatric brain tumor.
弥漫性内在脑桥神经胶质瘤是儿童中最具侵袭性的高级别神经胶质瘤,目前尚无有效的治疗方法。部分原因是对潜在生物学的理解不足,以及缺乏代表性的体外和体内模型,导致生存率没有提高。最近,已经发现使用活检和尸检肿瘤来生成培养物和异种移植模型是可行的。
为了进一步开发模型,我们评估了 8 个合作中心的国际经验,从患者来源的尸检和活检中生成 DIPG 临床前模型。进行了单变量和多变量分析,以确定与体外和体内 PDX 发展成功相关的关键因素。
从 57%的样本(活检的 84.2%和尸检的 38.2%)成功建立了体外培养物。在 DMEM 培养基中转移的样本比在 Hibernate A 中转移的样本更有可能建立成功的培养物。与尸检样本(38.2%)相比,活检样本(84.2%)更易成功建立体外培养物,而且更倾向于在层粘连蛋白包被的平板上作为单层培养,而不是作为神经球。从尸检样本成功建立的原代培养物比从活检样本建立的培养物更有可能在动物模型中植入(86.7%比 47.4%)。总的来说,当 DIPG 样本直接植入小鼠(68%)时,肿瘤植入比培养后(40.7%)更成功。
这项多中心研究提供了有关建立 DIPG 患者来源临床前模型成功率的有价值信息。这些结果可以进一步优化 DIPG 模型的开发,并最终有助于研究这种侵袭性小儿脑肿瘤的新疗法。